Goldman Sachs’s Cytek Biosciences CTKB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.46M | Sell |
1,016,557
-141,444
| -12% | -$481K | ﹤0.01% | 3067 |
|
|
2025
Q1 | $4.64M | Sell |
1,158,001
-183,751
| -14% | -$737K | ﹤0.01% | 2806 |
|
|
2024
Q4 | $8.71M | Buy |
1,341,752
+319,008
| +31% | +$2.07M | ﹤0.01% | 2444 |
|
|
2024
Q3 | $5.67M | Sell |
1,022,744
-334,507
| -25% | -$1.85M | ﹤0.01% | 2668 |
|
|
2024
Q2 | $7.57M | Buy |
1,357,251
+793,236
| +141% | +$4.43M | ﹤0.01% | 2312 |
|
|
2024
Q1 | $3.78M | Buy |
564,015
+1,236
| +0.2% | +$8.29K | ﹤0.01% | 2789 |
|
|
2023
Q4 | $5.13M | Buy |
562,779
+24,424
| +5% | +$223K | ﹤0.01% | 2568 |
|
|
2023
Q3 | $2.97M | Sell |
538,355
-30,040
| -5% | -$166K | ﹤0.01% | 2833 |
|
|
2023
Q2 | $4.85M | Buy |
568,395
+363,261
| +177% | +$3.1M | ﹤0.01% | 2586 |
|
|
2023
Q1 | $1.89M | Sell |
205,134
-156,988
| -43% | -$1.44M | ﹤0.01% | 3259 |
|
|
2022
Q4 | $3.7M | Buy |
362,122
+263,644
| +268% | +$2.69M | ﹤0.01% | 2860 |
|
|
2022
Q3 | $1.45M | Buy |
98,478
+23,586
| +31% | +$347K | ﹤0.01% | 3584 |
|
|
2022
Q2 | $803K | Sell |
74,892
-574,397
| -88% | -$6.16M | ﹤0.01% | 4094 |
|
|
2022
Q1 | $7M | Buy |
649,289
+589,229
| +981% | +$6.35M | ﹤0.01% | 2531 |
|
|
2021
Q4 | $980K | Sell |
60,060
-9,262
| -13% | -$151K | ﹤0.01% | 4035 |
|
|
2021
Q3 | $1.48M | Buy |
+69,322
| New | +$1.48M | ﹤0.01% | 3707 |
|